Oncologix Tech Stock Net Income
| OCLG Stock | USD 0.0001 0.00 0.00% |
Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Oncologix Tech, as well as the relationship between them.
Oncologix Tech's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Oncologix Tech's valuation are provided below:Oncologix Tech does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Oncologix |
Oncologix Tech 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Oncologix Tech's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Oncologix Tech.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Oncologix Tech on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Oncologix Tech or generate 0.0% return on investment in Oncologix Tech over 90 days. Oncologix Tech is related to or competes with TurnKey Capital. Oncologix Tech, Inc., a diversified medical holding company, provides health care services in the United States More
Oncologix Tech Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Oncologix Tech's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Oncologix Tech upside and downside potential and time the market with a certain degree of confidence.
Oncologix Tech Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oncologix Tech's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Oncologix Tech's standard deviation. In reality, there are many statistical measures that can use Oncologix Tech historical prices to predict the future Oncologix Tech's volatility.Oncologix Tech Backtested Returns
We have found three technical indicators for Oncologix Tech, which you can use to evaluate the volatility of the company. The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Oncologix Tech are completely uncorrelated.
Auto-correlation | 1.00 |
Perfect predictability
Oncologix Tech has perfect predictability. Overlapping area represents the amount of predictability between Oncologix Tech time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Oncologix Tech price movement. The serial correlation of 1.0 indicates that 100.0% of current Oncologix Tech price fluctuation can be explain by its past prices.
| Correlation Coefficient | 1.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Oncologix Tech reported net income of (2.37 Million). This is 100.19% lower than that of the Health Care Providers & Services sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 100.42% higher than that of the company.
Oncologix Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oncologix Tech's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Oncologix Tech could also be used in its relative valuation, which is a method of valuing Oncologix Tech by comparing valuation metrics of similar companies.Oncologix Tech is currently under evaluation in net income category among its peers.
Oncologix Fundamentals
| Return On Asset | -0.12 | |||
| Profit Margin | (0.38) % | |||
| Operating Margin | (0.13) % | |||
| Current Valuation | 3.18 M | |||
| Shares Outstanding | 340.13 M | |||
| Price To Earning | (0.03) X | |||
| Price To Sales | 0.17 X | |||
| Revenue | 2.85 M | |||
| Gross Profit | 614.41 K | |||
| EBITDA | (572.25 K) | |||
| Net Income | (2.37 M) | |||
| Cash And Equivalents | 86.31 K | |||
| Total Debt | 3.97 M | |||
| Current Ratio | 0.28 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (24.2 K) | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 191 | |||
| Beta | 1.27 | |||
| Market Capitalization | 612.23 K | |||
| Total Asset | 1.5 M | |||
| Retained Earnings | (49.86 M) | |||
| Working Capital | (3.35 M) | |||
| Current Asset | 1.31 M | |||
| Current Liabilities | 4.67 M | |||
| Z Score | -47.6 | |||
| Net Asset | 1.5 M |
About Oncologix Tech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oncologix Tech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncologix Tech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncologix Tech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Oncologix Pink Sheet
Oncologix Tech financial ratios help investors to determine whether Oncologix Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oncologix with respect to the benefits of owning Oncologix Tech security.